·5 min read
Biotech Intelligence #14: ADC Gold Rush — Why ADCs and Bispecifics Accounted for 7 of the 10 Largest China Deals
Antibody-drug conjugates dominate China's out-licensing pipeline. We analyze why Chinese companies have built durable advantages in ADC development, break down the Merck-Kelun platform deal, and track this week's CDE filings in the bispecific-ADC space.
ADCLicensingOncologyAbbVieCDE Filing